This study aimed to investigate the gene and protein expression of key inflammasome mediators in venous blood and skin biopsy samples from Brazilian psoriatic patients treated at the Pedro Ernesto University Hospital (HUPE). Samples were collected from both psoriatic patients and healthy controls. Gene expression was evaluated using quantitative reverse transcription polymerase chain reaction (qRT‒PCR), while protein levels were assessed through immunohistochemistry and multiplex immunoassays. Compared with those from control individuals, blood and skin biopsy samples from psoriatic patients had significantly higher mRNA levels of nucleotide-binding domain leucine-rich repeat (NLR) family pyrin domain containing receptor 1 (NLRP1), caspase-1, interleukin-1β (IL-1β), and interleukin-18 (IL-18). Immunohistochemical analysis revealed elevated protein levels of NLRP1, caspase-1, IL-1β, and IL-18 in psoriatic skin biopsies. Multiplex immunoassays revealed increased plasma levels of interferon-γ (IFN-γ), IL-1β, interleukin-17 A (IL-17 A), and tumor necrosis factor-α (TNF-α) in psoriatic patients. A positive correlation was observed between NLRP1 expression, disease severity, and the protein levels of IL-1β and TNF-α. In conclusion, in Brazilian psoriatic patients treated at HUPE, both blood and skin biopsy samples show increased expression of the NLRP1 inflammasome and its downstream mediators. Furthermore, NLRP1 expression is positively correlated with disease severity and the release of T helper 1-type cytokines, highlighting its potential role in the pathogenesis and progression of psoriasis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00403-025-04029-w | DOI Listing |
J Clin Aesthet Dermatol
February 2025
Ms. Romanelli and Dr. Gottlieb are with the Department of Dermatology and Department of Medicine, Division of Rheumatology at Icahn School of Medicine at Mount Sinai in New York, New York.
Psoriasis (PsO) is an immune-mediated, chronic inflammatory skin disease that significantly impairs quality of life. Its treatment landscape is rapidly evolving, providing better disease control. Here, we highlight updates in biologics, obtaining coverage for biologics under Medicare, the PsO-to-psoriatic arthritis (PsA) transition, and orally administered drugs, as presented at the 2024 Masterclass in Dermatology in Puerto Rico.
View Article and Find Full Text PDFRev Med Suisse
March 2025
Service de rhumatologie, Département de l'appareil locomoteur, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Rheumatologists face daily challenges in managing inflammatory rheumatic diseases (rheumatoid arthritis, axial spondylarthritis, and psoriatic arthritis). Significant advancements in our therapeutic arsenal have occurred over the past decades. However, achieving remission remains an unattainable goal for many patients, highlighting the need for new treatment options.
View Article and Find Full Text PDFInt J Mol Sci
March 2025
Department of Rheumatology, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, 1070 Bruxelles, Belgium.
The interleukin (IL)-17 family encompasses six structurally related pro-inflammatory cystine knot proteins, designated as IL-17A to IL-17F. Over the last decades, evidence has pointed to its role as a critical player in the development of inflammatory diseases such as psoriasis (PsO), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA). More specifically, IL-17A and IL-17F are overexpressed in the skin and synovial tissues of patients with these diseases, and recent studies suggest their involvement in promoting inflammation and tissue damage in axSpA and PsA.
View Article and Find Full Text PDFNat Rev Rheumatol
March 2025
Section of Musculoskeletal Disease, NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK.
Psoriatic arthritis (PsA) is anatomically much more heterogeneous than rheumatoid arthritis, as, beyond synovitis, it often also involves enthesitis, peritendinitis, tenosynovitis, osteitis and periostitis. This heterogeneity currently precludes a gold standard for objectively defining resolution of inflammation following treatment, with enthesitis posing a particular challenge. Despite these difficulties, we apply lessons learned from rheumatoid arthritis to describe how patients with PsA and an inadequate response to therapy can be designated within two patient subgroups, characterized by persistent inflammatory PsA (PIPsA) and non-inflammatory PsA (NIPsA), respectively.
View Article and Find Full Text PDFRheumatol Ther
March 2025
Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Introduction: Long-term treatment of psoriatic arthritis (PsA) is required to prevent progression. However, persistence with current treatments is challenging due to tolerability and acceptability issues. The objective of this study was to estimate 1-year persistence with secukinumab in patients with PsA treated with secukinumab, to compare persistence rates between secukinumab and adalimumab, to estimate usefulness rates, and to document adverse events.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!